Back to search

Article

Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world study

2025-08-03

Abstract excerpt

<title>Abstract</title> <p>Background The efficacy and safety of combining chemotherapy with different anti-PD-1 treatment as first-line treatment in advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in a real-world study remains unknown. Therefore, this real-world study investigated the efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous N...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a9b5eef1-4c93-5e00-8140-efa02395f7e2
DOI
10.21203/rs.3.rs-7161891/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studyDOI 10.21203/rs.3.rs-7161891/v1
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.Semantic proximity
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.Semantic proximity
Real-world Data Analysis of Immunotherapy in Advanced Lung CancerSemantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Efficacy and Safety Analysis of Camrelizumab, Sintilimab, and Tislelizumab in the Treatment of NSCLC in Xuanwei, China: A Retrospective Real-World StudySemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Effect of PD-1 inhibitor combined with chemotherapy on cytokines and immune cell function in patients with advanced lung cancerSemantic proximity
Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer.Semantic proximity
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity
Select a neighboring publication to make it the new centre.